Clinical Trial Update: Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether ultra-low dose naloxone can mitigate remifentanil-induced hyperalgesia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Hyperalgesia

Drugs mentioned

• Naloxone (Naloxone)
• Remifentanil (remifentanil)

Snippet

Sponsor: University of California, Irvine | Conditions: Hyperalgesia | Phase 2 | Status: TERMINATED